1. Adamietz IA, Czeloth K, Ganswindt U, Miller K, Perner S, Reske SN, Walz J, Wierecky J. Prostatakarzinom. Onkologe 2008; 14:1087-1102.
  2. Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine. Clin Cancer Res 2008; 14:2970-2977.
  3. Buck AK, Bommer M, Juweid ME, Glatting G, Stilgenbauer S, Mottaghy FM, Schulz M, Kull T, Bunjes D, Möller P, Döhner H, Reske SN. First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine. J. Nucl. Med. 2008; 49:1756-1762.
  4. Friesen C, Lubatschofski A, Glatting G, Debatin KM, Reske SN. Activation of intrinsic apoptotic pathway by Re-188 irradiation and paclitaxel in coronary artery smooth muscle cells. Q. J. Nucl. Med. Mol. Imaging 2008; 52:289-295. mit freundlicher Unterstützung der Deutschen José Carreras Leukämie-Stiftung e. V.
  5. Krüger S, Buck AK, Mottaghy FM, Pauls S, Schelzig H, Hombach V, Reske SN. Use of integrated FDG-PET/CT in sarcoidosis. Clin Imaging 2008; 32:269-273.
  6. Lassmann M, Glatting G. Grundlagen der patientenspezifischen Dosimetrie bei Radionuklidtherapien. Der Nuklearmediziner 2008; 31:93–100.
  7. Liu W, Zhou Y, Reske SN, Shen C. PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res 2008; 28:3613-3619.
  8. Ludolph AG, Kassubek J, Schmeck K, Glaser C, Wunderlich A, Buck AK, Reske SN, Fegert JM, Mottaghy FM. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study. Neuroimage 2008; 41:718-727.
  9. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardiere E, (EANM) EAoNM. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35:1941-1959.
  10. Maier H, Mühlmeier G, Kraft K, Blumstein NM, Tisch M. Primary malignant melanoma of the parotid gland: a case report and review of the literature. HNO 2008; 56:627-632.
  11. Morgenroth A, Deisenhofer S, Glatting G, Kunkel FH-G, Dinger C, Zlatopolskiy B, Vogg ATJ, Kull T, Reske SN. Preferential Tumor Targeting and Selective Tumor Cell Cytotoxicity of 5-[131/125I]Iodo-4`-thio-2`-Deoxyuridine. Clin Cancer Res 2008; 14:7311-7319.
  12. Morgenroth A, Deisenhofer S, Neininger M, Vogg AT, Glatting G, Kull T, Reske SN. Biodistribution, cellular uptake and DNA-incorporation of the 2'-fluoro stabilized 5-iodo-2'-deoxyuridine analog 5-iodo-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil (FIAU). Q J Nucl Med Mol Imaging 2008; 52:305-316.
  13. Neumaier B, Mottaghy FM, Buck AK, Glatting G, Blumstein NM, Mahren B, Vogg ATJ, Reske SN. 18F-Immuno-PET: Determination of anti-CD66 biodistribution in a patient with high risk leukaemia. Cancer Biother Radiopharm 2008; 23:819-824.
  14. Pauls S, Buck AK, Halter G, Mottaghy FM, Muche R, Bluemel C, Gerstner S, Krüger S, Glatting G, Sunder-Plassmann L, Möller P, Brambs HJ, Reske SN. Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions - Results from a Large Prospective Clinical Trial. Mol Imaging Biol 2008; 10:121-128.
  15. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab 2008; 22:989-1007.
  16. Reiners C, Dietlein M, Luster M. Malignant goiter-thyroid cancer. Dtsch Med Wochenschr 2008; 133:2215-2228.
  17. Reske SN, Blumstein NM, Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 2008; 35:9-17.
  18. Reske SN. FDG-PET and PET/CT in malignant lymphoma. Recent Results Cancer Res 2008; 170:93-107.
  19. Reske SN. [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008; 35:1740-1741.
  20. Reuter S, Grüner B, Buck AK, Blumstein N, Kern P, Reske SN. Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nuklearmedizin 2008; 47:147-152.
  21. Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, Wittbrodt M, Egghardt G, Moeller P, Blumstein N, Reske S, Kuefer R. [11C]Choline PET/CT for Targeted Salvage Lymph Node Dissection in Patients with Biochemical Recurrence after Primary Curative Therapy for Prostate Cancer. Urol Int. 2008; 81:191–197.
  22. Shen C, Zhou Y, Zhan J, Reske SN, Buck AK. Chromosome instability and tumor lethality suppression in carcinogenesis. J Cell Biochem 2008; 105:1327-1341.
  23. Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, Maljevic S, Margari L, Kamm C, Schneider SA, Huber SM, Pekrun A, Roebling R, Seebohm G, Koka S, Lang C, Kraft E, Blazevic D, Salvo-Vargas A, Fauler M, Mottaghy FM, Münchau A, Edwards MJ, Presicci A, Margari F, Gasser T, Lang F, Bhatia KP, Lehmann-Horn F, Lerche H. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J. Clin. Invest. 2008; 118:2157–2168.